User profiles for Alexandre Reuben
 | Alexandre Reuben, Ph.D.Assistant Professor, MD Anderson Cancer Center Verified email at mdanderson.org Cited by 18122 |
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Preclinical mouse models suggest that the gut microbiome modulates tumor response to
checkpoint blockade immunotherapy; however, this has not been well-characterized in human …
checkpoint blockade immunotherapy; however, this has not been well-characterized in human …
B cells and tertiary lymphoid structures promote immunotherapy response
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy.
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …
[PDF][PDF] Defining T cell states associated with response to checkpoint immunotherapy in melanoma
…, M Barzily-Rokni, SS Freeman, A Reuben… - Cell, 2018 - cell.com
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By
studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic …
studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic …
[PDF][PDF] The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy
…, BA Helmink, CN Spencer, A Reuben… - Cancer cell, 2018 - cell.com
The microbiome is receiving significant attention given its influence on a host of human
diseases including cancer. Its role in response to cancer treatment is becoming increasingly …
diseases including cancer. Its role in response to cancer treatment is becoming increasingly …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
…, CN Spencer, IF Curbelo, L Vence, A Reuben… - Nature medicine, 2021 - nature.com
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states
remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 …
remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 …
